Appeal No. 1997-1842
Application 08/068,878
1. A method for the chronic treatment for a period of at least two and one-half
years of urinary symptoms associated with benign prostatic hyperplasia comprising
administering to a male human patient in need of such treatment a therapeutically
effective amount of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-
furanyl)carbonyl]piperazine or a pharmaceutically acceptable salt thereof.
2. A method for the chronic treatment of urinary symptoms associated with
benign prostatic hyperplasia comprising administering to a male human patient in need
of such treatment a therapeutically-effective amount of 1-(4-amino-6,7-dimethoxy-2-
quinazolinyl)-4-[(tetrahydro-2-furanyl)-carbonyl]piperazine monohydrochloride dihydrate.
7. The method of Claim 1 wherein said therapeutically effective amount of
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine or a
pharmaceutically acceptable salt thereof is administered in the form of a soft elastic
gelatin capsule formulation in unit dosage form comprising between 1 mg and 20 mg
of active ingredient.
The references relied upon by the examiner are:
Lepor et al. (Lepor et al. 1988), “Laboratory Assessment of Terazosin and Alpha-1
Blockade in Prostatic Hyperplasia,” Urology, Supp. to Vol. 32 (6), pp. 21-26 (Dec.
1988).
Lepor, (Lepor 1989), “Role of Alpha-Adrenergic Blockers in the Treatment of Benign
Prostatic Hyperplasia,” The Prostate, Supp. 3, pp. 75-84 (1990), Proc. of the Urological
Assoc., Dallas, TX, May 6, 1989.
Lepor et al. (Lepor et al. 1989), “The Safety and Efficacy of Terazosin for the
Treatment of Benign Prostatic Hyperplasia,” Int. J. Clin. Pharmacol. Ther. Toxicol.,
27 (8), pp. 392-97 (Aug. 1989).
Dunzendorfer, “Effects of Terazosin in the Treatment of Benign Prostatic Hyperplasia,”
Arzneimittelforschung, 39 (1), pp. 1289-91 (Oct. 1989).
Fabricius et al. (Fabricius), “Efficacy of Once-A-Day Terazosin in Benign Prostatic
Hyperplasia: A Randomized, Double-Blind Placebo-Controlled Clinical Trial,” The
Prostate, Supp. 3, pp. 85-93 (1990).
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007